Manchester Pharmaceuticals, Inc. Company Profile

18:23 EST 21st November 2017 | BioPortfolio

Manchester Pharmaceuticals, a privately-held specialty pharmaceutical company, is focused on the identification, development and commercialization of new therapeutic modalities to address the special needs of patients with rare diseases. Manchester is actively pursuing the license and acquisition of additional new product opportunities in the rare disease area.

News Articles [640 Associated News Articles listed on BioPortfolio]

Troponin-Only Manchester ACS (T-MACS) Decision Aid

A refinement of the original Manchester Acute Coronary Syndromes model may help rule out ACS among patients presenting to the ED with chest pain. Emergency Medicine Journal

Manchester delegation seeking digital health partnerships in US

A delegation from Manchester is heading to the US to showcase the city’s strength in the life sciences sector.

UMI3 gives exclusive licence for SenTraGor to Arriani Pharmaceuticals

The University of Manchester’s technology transfer company, UMI3, has entered an exclusive licence deal with Arriani Pharmaceuticals for a research tool that helps clarify the role of senescent cell...

RCGP to work with Manchester on improving GP services

Greater Manchester Health and Social Care Partnership and the Royal College of GPs have signed a memorandum of understanding to deliver a new programme designed to improve GP services across the regio...

Ten-foot living structure in Manchester helps launch HIV has Changed campaign today

A national HIV awareness campaign is launching today (Thursday 7 September) on New Cathedral Street, Manchester.

Blueberry Therapeutics announces collaboration with the University of Manchester

Blueberry Therapeutics (Blueberry) today announced that it has launched a collaboration with the University of Manchester exploring the mode of action and therapeutic potential of novel antiflammator...

Offshore wind 'could be a bonanza' for UK says expert

(University of Manchester) As the world gathers in Bonn for COP23, the UN's annual climate change conference, Professor Mike Barnes, from The University of Manchester's School of Electrical & Electron...

New funding available to support Biotech and Healthcare SME collaborations with the University of Manchester

The University of Manchester has been awarded by the BBSRC a grant of £100K (‘Sparking Impact Award’) to support new partnerships between the University and small biotechnology and b...

PubMed Articles [138 Associated PubMed Articles listed on BioPortfolio]

Validating the Manchester Acute Coronary Syndromes (MACS) and Troponin-only Manchester Acute Coronary Syndromes (T-MACS) rules for the prediction of acute myocardial infarction in patients presenting to the emergency department with chest pain.

The Manchester Acute Coronary Syndromes (MACS) rule and the Troponin-only MACS (T-MACS) rule risk stratify patients with suspected acute coronary syndrome (ACS). This observational study sought to val...

Factors that influence care priority for chest pain patients using the manchester triage system.

Analyze crucial factors for determining care priority for patients with acute myocardial infarction based on the Manchester Triage System.

Effectiveness of the Manchester Triage System on time to treatment in the emergency department: a systematic review protocol.

The review aims to find the best available evidence on the effectiveness of the Manchester Triage System on time to treatment in the emergency department.

An exploration of patients' experiences of participation in a randomised controlled trial of the Manchester Acute Coronary Syndromes (MACS) decision rule.

As an important part of a pilot study to determine the feasibility of a large randomised controlled trial (RCT) comparing use of the Manchester Acute Coronary Syndromes (MACS) decision rule with stand...

Feasibility of the Manchester Acute Coronary Syndromes (MACS) decision rule to safely reduce unnecessary hospital admissions: a pilot randomised controlled trial.

Observational studies suggest that the Manchester Acute Coronary Syndromes (MACS) decision rule can effectively 'rule out' and 'rule in' acute coronary syndromes (ACS) following a single blood test. I...

Clinical Trials [221 Associated Clinical Trials listed on BioPortfolio]

A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy

This study will be co-ordinated by Dr Hector Chinoy, Dr Robert G Cooper (Salford Royal NHS Foundation Trust / The University of Manchester) and Dr Ian N Bruce (Central Manchester Universit...

Diagnostic Modeling for Pedal Fat Pad Atrophy

We hypothesize that there is a difference in plantar tissue thickness, plantar pressure, and pain score in patients diagnosed with plantar fat pad atrophy compared to healthy, foot-type ma...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Companies [1325 Associated Companies listed on BioPortfolio]

Manchester Pharmaceuticals, Inc.

Manchester Pharmaceuticals, a privately-held specialty pharmaceutical company, is focused on the identification, development and commercialization of new therapeutic modalities to address the special ...

Manchester United

Manchester United is one of the most popular and successful sports teams in the world, playing one of the most popular spectator sports on Earth. Through our 135-year heritage we ...

Medeval Ltd

Medeval was founded in 1983. Initially, Medeval facilities included a 6-bedded investigative unit and bioanalytical laboratory housed within the Pharmacy Department, University of Manchester. In its f...

Manchester College

Renovo plc

Renovo is the world leader in scar prevention and reduction research, developing pharmaceutical products to prevent and reduce scarring in the skin, blood vessels, eyes, nerves, internal organs, tendo...

More Information about "Manchester Pharmaceuticals, Inc." on BioPortfolio

We have published hundreds of Manchester Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of Manchester Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about Manchester Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Manchester Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant Manchester Pharmaceuticals, Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Corporate Database Quicklinks

Searches Linking to this Company Record